Middle East respiratory syndrome: Current status and future prospects for vaccine development

Expert Opinion on Biological Therapy

Volumn 15, Issue 11, 2015, Pages 1647-1651

  Du, Lanying ^a   Jiang, Shibo ^a,b  

^a NEW YORK BLOOD CENTER   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Animal models; Middle East respiratory syndrome; Middle East respiratory syndrome coronavirus; receptor binding domain; spike protein; vaccines

Indexed keywords

MIDDLE EAST RESPIRATORY SYNDROME VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR; RECOMBINANT PROTEIN; VIRUS VACCINE;

DRUG RESEARCH; DRUG TARGETING; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; VIRUS STRAIN; ANIMAL; BIOSYNTHESIS; CORONAVIRUS INFECTIONS; DISEASE MODEL; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; VIROLOGY;

ANIMALS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; RECOMBINANT PROTEINS; VIRAL VACCINES;

EID: 84946495956     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1092518     Document Type: Review

References (41)

1. Zaki AM, Van BS, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814-20
2. Memish ZA, Mishra N, Olival KJ, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 2013;19(11):1819-23
3. Madani TA, Azhar EI, Hashem AM. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014;371(14):1360
4. WHO. Middle East Respiratory Syndrome coronavirus (MERS-CoV) - Saudi Arabia. Available from: http://www.who.int/csr/don/27-august-2015-mers-saudi-arabia/en/ [Last accessed 27 August 2015]
5. Oboho IK, Tomczyk SM, Al-Asmari AM, et al. 2014 MERS-CoV outbreak in Jeddah - a link to health care facilities. N Engl J Med 2015;372(9):846-54
6. Maltezou HC, Tsiodras S. Middle East respiratory syndrome coronavirus: implications for health care facilities. Am J Infect Control 2014;42(12):1261-5
7. Almazan F, DeDiego ML, Sola I, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio 2013;4(5):e00650-13
8. Totura AL, Baric RS. SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol 2012;2(3):264-75
9. Scobey T, Yount BL, Sims AC, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 2013;110(40):16157-62
10. Li F. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol 2015;89(4):1954-64
11. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495(7440):251-4
12. Muth D, Corman VM, Meyer B, et al. Infectious Middle East respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. J Clin Microbiol 2015;53(9):2951-5
13. Drosten C, Muth D, Corman VM, et al. An observational, laboratory-based study of outbreaks of middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis 2015;60(3):369-77
14. Kim E, Okada K, Kenniston T, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine 2014;32(45):5975-82
15. Guo X, Deng Y, Chen H, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 2015;145(4):476-84
16. Volz A, Kupke A, Song F, et al. Protective efficacy of recombinant modified vaccinia virus ankara (MVA) delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 2015;89(16):8651-6
17. Song F, Fux R, Provacia LB, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol 2013;87(21):11950-4
18. Paddock C. MERS vaccine 'ready for human trials'. Medical News Today. Available from: http://www.medicalnewstoday.com/articles/296023.php [Last accessed 29 June 2015]
19. Mou H, Raj VS, van Kuppeveld FJ, et al. The receptor binding domain of the new MERS coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16):9379-83
20. Du L, Zhao G, Kou Z, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol 2013;87(17):9939-42
21. Ma C, Wang L, Tao X, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments - the importance of immunofocusing in subunit vaccine design. Vaccine 2014;32(46):6170-6
22. Ma C, Li Y, Wang L, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine 2014;32(18):2100-8
23. Zhang N, Channappanavar R, Ma C, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2015. doi: 10.1038/cmi.2015.03. [Epub ahead of print]
24. Tang J, Zhang N, Tao X, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother 2015;11(5):1244-50
25. Muthumani K, Falzarano D, Reuschel EL, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med 2015;7(301):301ra132
26. Inovio News Release. Inovio pharmaceuticals partners with geneone life science for MERS immunotherapy clinical development. Available from: http://ir.inovio.com/news/news-releases/news-releases-details/2015/Inovio-Pharmaceuticals-Partners-with-GeneOne-Life-Science-for-MERS-Immunotherapy-Clinical-Development/default.aspx [Last accessed 27 May 2015]
27. Wang L, Shi L, Joyce MG, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015;6:7712
28. Coleman CM, Liu YV, Mu H, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 2014;32(26):3169-74
29. Zhao J, Perera RA, Kayali G, et al. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. J Virol 2015;89(11):6117-20
30. Falzarano D, de Wit E, Feldmann F, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog 2014;10(8):e1004250
31. de Wit E, Rasmussen AL, Falzarano D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013;110(41):16598-603
32. Adney DR, Van DN, Brown VR, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis 2014;20(12):1999-2005
33. Zhao J, Li K, Wohlford-Lenane C, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA 2014;111(13):4970-5
34. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of middle East respiratory syndrome coronavirus infection and disease. J Virol 2015;89(7):3659-70
35. Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol 2013;11(12):836-48
36. Du L, Zhao G, Yang Y, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014;88(12):7045-53
37. Ying T, Du L, Ju TW, et al. Exceptionally potent neutralization of middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 2014;88(14):7796-805
38. Jiang L, Wang N, Zuo T, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014;6(234):234ra59
39. Weingartl H, Czub M, Czub S, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 2004;78(22):12672-6
40. He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006;176(10):6085-92
41. Lan J, Deng Y, Chen H, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 2014;9(11):e112602